Evolution of the Average Target: AtriCure, Inc.

Evolution of the Average Target - AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Evolution of the Target Price - AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

dba1bb595e6172b2ee717423f8c.OiZ2SI2wFQEbjJEmOxo0xw_pjQjEt1KXkB_z5VPV5x0.U2QgBsbcWlRLvaZIaUhT8UiiuGOUwjfSxnm_hBbmuHZwZwFl28pBdUHo5g~fc053bc65a11a94e6eba1ea7f698f4f3
11-04 Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy Rating MT
09-02 Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating MT
07-28 UBS Adjusts Price Target on AtriCure to $50 From $55, Maintains Buy Rating MT
02-18 UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating MT
02-18 Oppenheimer Downgrades AtriCure to Market Perform From Outperform MT
02-11 AtriCure Shares Fall After JPMorgan Downgrade MT
02-11 Top Midday Decliners MT
02-11 JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48 MT
30/07/25 Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating MT
30/07/25 AtriCure Q2 revenue beats estimates RE
30/04/25 UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating MT
28/03/25 Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating MT
13/02/25 Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating MT
30/10/24 UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating MT
31/07/24 Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating MT
02/05/24 Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating MT
23/04/24 Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32 MT
16/02/24 UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating MT
16/02/24 Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating MT
16/02/24 Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating MT
22/01/24 UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating MT
23/10/23 JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60 MT
29/09/23 UBS Initiates AtriCure With Buy Rating, Price Target is $56 MT
26/07/23 Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating MT
03/05/23 Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.16%
+9.57%
+2.08%
+9.6%
+18.41%
+6.51%
+3.72%
+1.84%
+27.74%
+20.55%
Average +11.42%
Weighted average by Cap. +9.81%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
55.31USD
Average target price
64.89USD
Spread / Average Target
+17.32%
High Price Target
70.00USD
Spread / Highest target
+26.56%
Low Price Target
50.00USD
Spread / Lowest Target
-9.60%

Analyst Consensus Detail

Analyst consensus - AtriCure, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AtriCure, Inc.
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - AtriCure, Inc.
  1. Stock Market
  2. Stocks
  3. ATRC Stock
  4. Consensus AtriCure, Inc.